NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.9200
-0.0299 (-3.15%)
At close: Jan 30, 2026, 4:00 PM EST
0.9384
+0.0184 (2.00%)
After-hours: Jan 30, 2026, 7:27 PM EST
NeuroSense Therapeutics Market Cap
NeuroSense Therapeutics has a market cap or net worth of $30.46 million as of January 30, 2026. Its market cap has increased by 27.27% in one year.
Market Cap
30.46M
Enterprise Value
29.80M
1-Year Change
27.27%
Ranking
Category
Stock Price
$0.92
Market Cap Chart
Since the IPO on December 9, 2021, NeuroSense Therapeutics's market cap has decreased from $64.61M to $30.46M, a decrease of -52.85%. That is a compound annual growth rate of -16.59%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jan 30, 2026 | 30.46M | 33.39% |
| Dec 31, 2025 | 22.84M | -17.70% |
| Dec 31, 2024 | 27.75M | 158.68% |
| Dec 29, 2023 | 10.73M | -24.68% |
| Dec 30, 2022 | 14.24M | -46.24% |
| Dec 31, 2021 | 26.49M | -59.00% |
| Dec 9, 2021 | 64.61M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Lixte Biotechnology Holdings | 32.41M |
| Skye Bioscience | 32.38M |
| Outlook Therapeutics | 32.32M |
| Werewolf Therapeutics | 32.11M |
| Kyntra Bio | 31.88M |
| Dyadic International | 31.52M |
| AN2 Therapeutics | 30.96M |
| Cue Biopharma | 30.55M |